Trial Profile
Atorvastatin for the prevention of coronary heart disease endpoints in patients with NIDDM (ASPEN)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary)
- Indications Cardiovascular disorders
- Focus Therapeutic Use
- Acronyms ASPEN
- 05 Nov 2010 New trial record.